← Leaderboards
Alan Remaley
Clinical Center
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Lipoproteins”
- Daniel James Rader · University Of Pennsylvania$60,032,323
- Ronald M Krauss · University Of Calif-Lawrenc Berkeley Lab$36,739,596
- Ira Jay Goldberg · New York University School Of Medicine$36,438,332
- Alan Richard Tall · Columbia University Health Sciences$33,957,001
- Eric A Boerwinkle · University Of Texas Hlth Sci Ctr Houston$32,518,468
- Stephen G Young · J. David Gladstone Institutes$31,888,335
Research focus
LipoproteinsHigh Density LipoproteinsCholesterolPublishingCardiovascular DiseasesAtherosclerosisMetabolismAnimal ModelPlasmaClinical TrialsTriglyceridesParticleFutureIn VivoLipidsMouse ModelBaseCardiovascular Risk FactorApolipoprotein A-IPhosphatidylcholine-Sterol O-AcyltransferaseInfusion ProceduresTissuesInflammationPeptides
Grant awards (76)
Role of fatty acids in health and disease.$1,685,715
ZIA · FY2025 · HL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$1,636,135
ZIA · FY2025 · HL · contact PI
Development and assessment of cardiovascular risk biomarkers$1,636,135
ZIA · FY2025 · HL · contact PI
Role of fatty acids in health and disease.$1,607,467
ZIA · FY2024 · HL · contact PI
Development and assessment of cardiovascular risk biomarkers$1,560,188
ZIA · FY2024 · HL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$1,560,188
ZIA · FY2024 · HL · contact PI
Role of fatty acids in health and disease.$1,503,488
ZIA · FY2023 · HL · contact PI
Development and assessment of cardiovascular risk biomarkers$1,459,268
ZIA · FY2023 · HL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$1,459,268
ZIA · FY2023 · HL · contact PI
Role of fatty acids in health and disease.$1,411,821
ZIA · FY2022 · HL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$1,317,710
ZIA · FY2022 · HL · contact PI
Development and assessment of cardiovascular risk biomarkers$1,317,710
ZIA · FY2022 · HL · contact PI
Role of fatty acids in health and disease.$1,469,102
ZIA · FY2021 · HL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$1,425,893
ZIA · FY2021 · HL · contact PI
Development of recombinant Lecithin Cholesterol Acyltransferase as a therapeutic$1,425,893
ZIA · FY2021 · HL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$1,447,817
ZIA · FY2020 · HL · contact PI
Role of fatty acids in health and disease.$1,447,817
ZIA · FY2020 · HL · contact PI
Development of recombinant Lecithin Cholesterol Acyltransferase as a therapeutic$1,447,817
ZIA · FY2020 · HL · contact PI
Use Of Animal Models To Study Genes That Modulate Atherosclerosis$1,030,857
ZIA · FY2019 · HL · contact PI
Role of fatty acids in health and disease.$1,030,857
ZIA · FY2019 · HL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$1,030,857
ZIA · FY2019 · HL · contact PI
Development of recombinant Lecithin Cholesterol Acyltransferase as a therapeutic$1,030,857
ZIA · FY2019 · HL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$1,862,584
ZIA · FY2018 · HL · contact PI
Use Of Animal Models To Study Genes That Modulate Atherosclerosis$1,390,606
ZIA · FY2018 · HL · contact PI
Development of recombinant Lecithin Cholesterol Acyltransferase as a therapeutic$1,390,606
ZIA · FY2018 · HL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$1,752,138
ZIA · FY2017 · HL · contact PI
Use Of Animal Models To Study Genes That Modulate Atherosclerosis$1,311,932
ZIA · FY2017 · HL · contact PI
Development of recombinant Lecithin Cholesterol Acyltransferase as a therapeutic$1,311,932
ZIA · FY2017 · HL · contact PI
Development and Investigation of Assays For Cardiovascular Risk Assessment$0
ZIA · FY2017 · CL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$1,483,373
ZIA · FY2016 · HL · contact PI
Use Of Animal Models To Study Genes That Modulate Atherosclerosis$1,112,530
ZIA · FY2016 · HL · contact PI
Development of recombinant Lecithin Cholesterol Acyltransferase as a therapeutic$1,112,530
ZIA · FY2016 · HL · contact PI
Development and Investigation of Assays For Cardiovascular Risk Assessment$0
ZIA · FY2016 · CL · contact PI
Use Of Animal Models To Study Genes That Modulate Atherosclerosis$995,167
ZIA · FY2015 · HL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$965,897
ZIA · FY2015 · HL · contact PI
Development of recombinant Lecithin Cholesterol Acyltransferase as a therapeutic$965,897
ZIA · FY2015 · HL · contact PI
Development and Investigation of Assays For Cardiovascular Risk Assessment$0
ZIA · FY2015 · CL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$1,300,838
ZIA · FY2014 · HL · contact PI
Use Of Animal Models To Study Genes That Modulate Atherosclerosis$1,262,578
ZIA · FY2014 · HL · contact PI
Development of recombinant Lecithin Cholesterol Acyltransferase as a therapeutic$1,262,578
ZIA · FY2014 · HL · contact PI
Development and Investigation of Assays For Cardiovascular Risk Assessment$0
ZIA · FY2014 · CL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$1,065,405
ZIA · FY2013 · HL · contact PI
Development of recombinant Lecithin Cholesterol Acyltransferase as a therapeutic$1,065,405
ZIA · FY2013 · HL · contact PI
Use Of Animal Models To Study Genes That Modulate Atherosclerosis$1,065,405
ZIA · FY2013 · HL · contact PI
Use Of Animal Models To Study Genes That Modulate Atherosclerosis$1,019,615
ZIA · FY2012 · HL · contact PI
Regulation of lipid metabolism by miRNAs$994,754
ZIA · FY2012 · HL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$663,169
ZIA · FY2012 · HL · contact PI
Development of recombinant Lecithin Cholesterol Acyltransferase as a therapeutic$663,169
ZIA · FY2012 · HL · contact PI
Development and Investigation of Assays For Cardiovascular Risk Assessment$0
ZIA · FY2012 · CL · contact PI
Use Of Animal Models To Study Genes That Modulate Atherosclerosis$1,057,935
ZIA · FY2011 · HL · contact PI
Regulation of lipid metabolism by miRNAs$1,032,935
ZIA · FY2011 · HL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$688,623
ZIA · FY2011 · HL · contact PI
Development of recombinant Lecithin Cholesterol Acyltransferase as a therapeutic$688,623
ZIA · FY2011 · HL · contact PI
Use Of Animal Models To Study Genes That Modulate Atherosclerosis$975,803
ZIA · FY2010 · HL · contact PI
Regulation of lipid metabolism by miRNAs$975,803
ZIA · FY2010 · HL · contact PI
Development of recombinant Lecithin Cholesterol Acyltransferase as a therapeutic$650,536
ZIA · FY2010 · HL · contact PI
Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease$650,536
ZIA · FY2010 · HL · contact PI
Development and Investigation of Assays For Cardiovascular Risk Assessment$0
ZIA · FY2010 · CL · contact PI
Use Of Animal Models To Study Lipid Genes That Modulate Atherosclerosis$3,050,679
ZIA · FY2009 · HL · contact PI
Development Of New Assays For Lipoprotein Testing$0
ZIA · FY2009 · CL · contact PI
Use Of Animal Models To Study Lipid Genes That Modulate Atherosclerosis$2,559,154
Z01 · FY2008 · HL · contact PI
Development Of New Assays For Lipoprotein Testing$41,715
Z01 · FY2008 · CL · contact PI
Use Of Animal Models To Study Lipid Genes That Modulate Atherosclerosis$3,245,489
Z01 · FY2007 · HL · contact PI
Development Of New Assays For Lipoprotein Testing$39,000
Z01 · FY2007 · CL · contact PI
Use Of Animal Models To Study Lipid Genes That Modulate$0
Z01 · FY2006 · HL · contact PI
Development Of New Assays For Lipoprotein Testing$0
Z01 · FY2006 · CL · contact PI
Development and Clinical Assessment of an Immunoassay fo$0
Z01 · FY2005 · CL
Develop and Assess of Immunoassay for Serum Mesothelin$0
Z01 · FY2004 · CL
Development Of New Assays For Lipoprotein Testing$0
Z01 · FY2003 · CL
Development Of New Assays For Lipoprotein Testing$0
Z01 · FY2002 · CL
lopment And Diagnostic Use Of Rapid Immunoassays$0
Z01 · FY2002 · CL
Method Development: Lipoprotein fraction analysis$0
Z01 · FY2001 · CL
Development And Diagnostic Use Of Rapid Immunoassays$0
Z01 · FY2001 · CL
Development of New Assays for Lipoprotein Testing$0
Z01 · FY2000 · CL
IMMUNOASSAY OF TUMOR MARKERS FROM TISSUE$0
Z01 · FY2000 · CL
Development and Diagnostic Use of Rapid Immunoassays$0
Z01 · FY2000 · CL